The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats

BACKGROUND: The advent of proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting drugs have provided an effective, but extremely expensive treatment for the management of low density lipoprotein (LDL). Our aim was to explore a cost-effective application of camelid anti-PCSK9 single domain...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinyang, Wang, Meiniang, Zhang, Xinhua, Liu, Chuxin, Xiang, Haitao, Huang, Mi, Ma, Yingying, Gao, Xiaoyan, Jiang, Lin, Liu, Xiaopan, Li, Bo, Hou, Yong, Zhang, Xiuqing, Yang, Shuang, Yang, Naibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018876/
https://www.ncbi.nlm.nih.gov/pubmed/32056048
http://dx.doi.org/10.1186/s40169-020-0265-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018876/
https://www.ncbi.nlm.nih.gov/pubmed/32056048
http://dx.doi.org/10.1186/s40169-020-0265-2

Ejemplares similares